Tricia B.

Tricia B. has extensive experience in clinical development operations, currently serving as Senior Vice President at BridgeBio since March 2019. Tricia leads clinical operations for various initiatives, including the execution of trials for ribitol in Limb Girdle Muscular Dystrophy Type 2i and managing the successful approval of NULIBRY for MOCD Type A. Prior roles include Executive Director of Global Clinical Operations at NCGS, Inc., Director of Global Clinical Trial Strategy & Operations at Bristol-Myers Squibb, and Director of Global Clinical Development at Teva Pharmaceuticals, where Tricia was instrumental in leading significant clinical submissions for treatments in migraine, headache, and neuroinflammation. Tricia began her career at Novartis, advancing through various roles in global clinical science and operations. Educational credentials include a B.S. in Biology from Arizona State University and a Master's in Biotechnology from Columbia University.